Comment
doi: 10.1016/S1470-2045(18)30073-1.
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
Affiliations
- PMID: 29508749
- DOI: 10.1016/S1470-2045(18)30073-1
Item in Clipboard
Comment
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer
Lancet Oncol.
2018 Mar.
No abstract available
Comment in
-
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.Lancet Oncol. 2018 Mar;19(3):e127. doi: 10.1016/S1470-2045(18)30133-5. Lancet Oncol. 2018. PMID: 29508752 No abstract available.
Comment on
-
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
Similar articles
-
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.Lancet Oncol. 2018 Mar;19(3):e126. doi: 10.1016/S1470-2045(18)30071-8. Lancet Oncol. 2018. PMID: 29508751 No abstract available.
-
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.Lancet Oncol. 2018 Mar;19(3):e125. doi: 10.1016/S1470-2045(18)30074-3. Lancet Oncol. 2018. PMID: 29508750 No abstract available.
-
Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.Lancet Oncol. 2018 Mar;19(3):e127. doi: 10.1016/S1470-2045(18)30133-5. Lancet Oncol. 2018. PMID: 29508752 No abstract available.
-
Vinorelbine (Navelbine) in the adjuvant and neoadjuvant treatment of non-small cell lung cancer.Semin Oncol. 1994 Oct;21(5 Suppl 10):64-71; discussion 71-2. Semin Oncol. 1994. PMID: 7973771 Review.
-
Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.N Z Med J. 2006 Nov 17;119(1245):U2310. N Z Med J. 2006. PMID: 17146485 Review.
Cited by
-
Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers.Transl Lung Cancer Res. 2019 Dec;8(6):967-978. doi: 10.21037/tlcr.2019.12.02. Transl Lung Cancer Res. 2019. PMID: 32010575 Free PMC article.
-
Image-guided drug delivery of nanotheranostics for targeted lung cancer therapy.Theranostics. 2022 May 13;12(9):4147-4162. doi: 10.7150/thno.72803. eCollection 2022. Theranostics. 2022. PMID: 35673583 Free PMC article.
-
Survival analysis in Caucasian pulmonary adenocarcinoma patients based on differential targets between Caucasian and Asian population.Saudi J Biol Sci. 2018 Jul;25(5):1003-1006. doi: 10.1016/j.sjbs.2018.05.023. Epub 2018 May 22. Saudi J Biol Sci. 2018. PMID: 30108455 Free PMC article.
-
EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients.Transl Cancer Res. 2019 Jan;8(Suppl 1):S23-S47. doi: 10.21037/tcr.2018.10.06. Transl Cancer Res. 2019. PMID: 35117062 Free PMC article. Review.
-
Recurrence risk after preoperative biopsy in patients with resected early-stage non-small-cell lung cancer: a retrospective study.Cancer Manag Res. 2018 Jul 6;10:1927-1934. doi: 10.2147/CMAR.S166930. eCollection 2018. Cancer Manag Res. 2018. PMID: 30013399 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
